US Patent 11401256 Dihydroquinolinones for medical treatment
Patent 11401256 was granted and assigned to C4 Therapeutics on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Nov, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Adrian Britschgi0
Annick Goergler0
Eric Andre Kusznir0
Fabian Dey0
Moreno Attilio Wichert0
Roger Norcross0
Edits on 25 Mar, 2023
Golden AI
Infobox
Edits on 27 Sep, 2022
Golden AI
Infobox
Edits on 26 Sep, 2022
Golden AI
Infobox
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114012560
Date of Patent
August 2, 2022
0Patent Application Number
168093450
Date Filed
March 4, 2020
0Patent Citations
Patent Primary Examiner
Edits on 3 Aug, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+332 characters)
US Patent 11401256 Dihydroquinolinones for medical treatment
Article
The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11401256
Date of patent
August 2, 2022
Patent application number
16809345
Date Filed
March 4, 2020
Patent citations
Patent primary examiner
Find more entities like US Patent 11401256 Dihydroquinolinones for medical treatment
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
